The Pipeline for New MASLD & MASH Treatments is Promising, says Naim Alkhouri, MD

Naim Alkhouri, MD, chief medical officer, chief of transplant hepatology, and director of the fatty liver program at Arizona Liver Health, in Phoenix, said that he and fellow researchers investigating treatments for metabolic dysfunction-associated liver disease, or MASLD, and metabolic dysfunction-associated steatohepatitis, or MASH, have their work cut out for them for a decade, at least. In a recent interview with Patient Care® Alkhouri offered a topline review of molecules currently moving through phase 2 and phase 3 clinical trials.

Other videos in this series with Dr Alkhouri:

• A MASLD Mantra to Practice By: Screen, Stage, Treat

• The FDA Approval of Resmetirom for MASH Changes Everything—for Patients and their Physicians

• Early Detection of MASLD in Primary Care: The Essentials with Naim Alkhouri, MD

• The Rate of Undetected MASLD in the US is a Sobering Statistic, says Expert Hepatologist Naim Alkhouri, MD